RxDoctor Payments Data

Zachary Wright, MD

Medical Oncology · Pensacola, FLNPI 1497982029

Payments from drug & device makers

$168,298in general payments, 2019–2025

Across 372 payments — averaging $452.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$100K
  • Merck$63K
  • Sanofi$1K
  • Novartis$584
  • Bristol Myers Squibb$363
  • E.r. Squibb & Sons, L.L.C.$267
  • plus $3K from 40 others

What the payments were for

  • Speaking & faculty fees$147,65488%
  • Travel & lodging$12,6918%
  • Food & beverage$7,9115%
  • Education$420%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$168,298 in reported general payments places this provider in the 70th percentile of 507 medical oncology providers in Florida.

See all medical oncology providers in Florida

Medicare billing

Part B allowed, 2024
$136,563
Medicare patients
522
Services billed
1,549

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib30$454,357
ImbruvicaIbrutinib30$446,675
RevlimidLenalidomide18$314,054
Abiraterone Acetate53$119,601
Imatinib Mesylate12$88,495
Deferasirox11$23,575
EliquisApixaban21$17,444
Enoxaparin Sodium16$5,007
Exemestane27$4,254
Anastrozole107$2,546
Oxycodone Hcl72$1,570
Hydrocortisone12$1,401
Hydroxyurea45$1,369
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen35$1,265
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen38$1,127

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Eliquis$80$471,80151 claims
Bristol Myers SquibbRevlimid$363$314,05418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 507 medical oncology providers in Florida.

Other medical oncology in Pensacola

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →